- Home
- PENG vs KURA Comparison
PENG vs KURA Comparison
Compare PENG & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PENG
- KURA
- Stock Information
- Founded
- PENG 1988
- KURA 2014
- Country
- PENG Cayman Islands
- KURA United States
- Employees
- PENG N/A
- KURA N/A
- Industry
- PENG Semiconductors
- KURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PENG Technology
- KURA Health Care
- Exchange
- PENG Nasdaq
- KURA Nasdaq
- Market Cap
- PENG 830.2M
- KURA 793.2M
- IPO Year
- PENG 2017
- KURA N/A
- Fundamental
- Price
- PENG $19.98
- KURA $8.98
- Analyst Decision
- PENG Strong Buy
- KURA Strong Buy
- Analyst Count
- PENG 6
- KURA 10
- Target Price
- PENG $24.17
- KURA $30.13
- AVG Volume (30 Days)
- PENG 982.9K
- KURA 2.0M
- Earning Date
- PENG 01-08-2025
- KURA 11-07-2024
- Dividend Yield
- PENG N/A
- KURA N/A
- EPS Growth
- PENG N/A
- KURA N/A
- EPS
- PENG N/A
- KURA N/A
- Revenue
- PENG $1,170,796,000.00
- KURA N/A
- Revenue This Year
- PENG N/A
- KURA N/A
- Revenue Next Year
- PENG N/A
- KURA $106.66
- P/E Ratio
- PENG N/A
- KURA N/A
- Revenue Growth
- PENG N/A
- KURA N/A
- 52 Week Low
- PENG $14.87
- KURA $8.75
- 52 Week High
- PENG $29.81
- KURA $24.17
- Technical
- Relative Strength Index (RSI)
- PENG N/A
- KURA 23.56
- Support Level
- PENG N/A
- KURA $8.75
- Resistance Level
- PENG N/A
- KURA $10.02
- Average True Range (ATR)
- PENG 0.00
- KURA 0.45
- MACD
- PENG 0.00
- KURA 0.13
- Stochastic Oscillator
- PENG 0.00
- KURA 9.75
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.